Article
Data published in Clinical and Translational Radiation Oncology Peer-reviewed clinical case study reported preliminary data on the first-in-human administration of NBTXR3 for the treatment of pancreatic cancer not eligible for surgery, demonstrating feasibility with no treatment-related toxicity Case study provides the first demonstration of local endoscopic delivery of NBTXR3 to a deep visceral tumor, and…
Read More
Company’s reSept™ ASD Occluder Aims to Evolve Septal Closure with its Novel Metal-Free Frame Design Excerpt from the Press Release: BAAR, Switzerland and SANTA CLARA, Calif., Feb. 8, 2022 /PRNewswire/ — atHeart Medical, a medical device company dedicated to establishing the new standard of care for closure of atrial septal defects (ASD), today announced it has received approval for the start…
Read More
– In vitro studies indicate IGM-6268 exhibits potent neutralization activity against the Omicron variant and all other Variants of Concern and Variants of Interest tested – – IGM-6268 Phase 1 clinical trials advancing in U.S. and South Africa – Excerpt from the Press Release: MOUNTAIN VIEW, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq:…
Read More
Excerpt from the Press Release: MARLBOROUGH, Mass. & PRINCETON, N.J.–(BUSINESS WIRE)–Sunovion Pharmaceuticals Inc. (Sunovion) and Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) today announced that the first patient has been randomized in SEP380-301, a Phase 3 clinical study evaluating non-racemic amisulpride (SEP-4199) for the treatment of major depressive episodes associated with bipolar I disorder (bipolar depression). Non-racemic amisulpride…
Read More
Broad, durable, and systemic anti-tumor immunity observed using inCPMV with OX40 agonist antibodies Intratumoral inCPMV administration in combination with systemic anti-OX40 controlled the progression of the primary as well as secondary untreated tumors 70% of animals survived for at least 100 days post tumor challenge without development of recurrence or metastatic disease Excerpt from the…
Read More
– Two studies evaluate ARD-101 in Obesity: one in General Obesity and the other in Refractory Weight Gain Post-Bariatric Surgery – The 3rd clinical trial is in Prader-Willi Syndrome, a rare genetic disorder characterized by persistent hyperphagia Excerpt from the Press Release: SAN DIEGO, Feb. 2, 2022 /PRNewswire/ — Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company focused…
Read More
Excerpt from the Press Release: Independent safety review completed with no toxicity concerns Cohort builds on prior proof-of-concept data demonstrating clinical benefit of pelareorep-checkpoint inhibitor combination in pancreatic cancer Multi-indication trial being conducted in collaboration with Roche and AIO also includes cohorts in metastatic colorectal and advanced anal cancers SAN DIEGO and CALGARY, AB, Feb. 2, 2022 /PRNewswire/ — Oncolytics…
Read More
— ENVISION Study Design Similar to Successful UGN-102 Phase 2b OPTIMA II Trial — Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced the initiation of its Phase 3 ENVISION study of UGN-102 (mitomycin)…
Read More
Excerpt from the Press Release: LEXINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3. According to the Centers for Disease Control and Prevention, the Omicron variant of the SARS-CoV-2 virus…
Read More
Excerpt from the Press Release: ZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Calif., February 2, 2022 – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today…
Read More